Condition: Autoimmune Diseases · Sponsor: Liang Zou
This study is an investigator-initiated single center, single arm clinical study with a target population of patients with refractory autoimmune diseases. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of CD19/BCMA CAR-T in the treatment of refractory autoimmune diseases.
This description comes directly from the study's public registry record.
Liang Zou, Doctor · +86 186 0270 1800 · zozozou@qq.com
Xiaoya Du · +86 27 8533 2028
Always discuss trial participation with your own doctor first.
| Wuhan No.1 Hospital | Wuhan, Hubei, China | Not Yet Recruiting |
| Wuhan No.1 Hospital | Wuhan, Hubei, China | Recruiting |
| Wuhan No.1 Hospital | Wuhan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07490951